KU-32, a Novel Drug for Diabetic Neuropathy, Is Safe for Human Islets and Improves In Vitro Insulin Secretion and Viability

Figure 2

KU-32 increased oxygen consumption per islet. Exposure to KU-32 increased oxygen consumption per islet through an 18-hour period. Measurements were made in triplicate wells with 13–33 islet equivalents (IE)/well.